A Double-Blinded, Multi-Center, Randomized, Placebo-Controlled Study to Investigate the Efficacy and Safety of Injectafer (Ferric Carboxymaltose) in the Treatment of Restless Legs Syndrome (RLS)
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Apr 2018
At a glance
- Drugs Ferric carboxymaltose (Primary)
- Indications Restless legs syndrome
- Focus Registrational; Therapeutic Use
- Sponsors Luitpold Pharmaceuticals
- 13 Apr 2018 This trial has been completed in Czech Republic, according to European Clinical Trials Database record.
- 06 Mar 2018 This trial has been completed in Poland, according to European Clinical Trials Database record.
- 18 Jan 2018 Planned End Date changed from 1 Apr 2018 to 1 Dec 2018.